Autopsy report · NCT04195958

A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma

“Due to low enrollment, this study was terminated early.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 year before it started.
• Ran for about 11 months before it stopped.
• 3 participants enrolled.
• Results were posted on the registry 5 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

Genentech, Inc.

Sponsor type

Industry

Conditions

Moderate-to-severe Allergic Asthma

Interventions

Omalizumab

Participants

3

Sites

12

Countries

United States

Trials that died the same way

• MIRACLE EF Clinical Study
  “The study was terminated early due to low enrollment.” (98% match in meaning)
• A Study of Fuzeon (Enfuvirtide) With an Integrase Inhibitor Plus Optimized Background in Treatment-Experienced HIV-1 Infected Patients
  “This study was terminated early due to poor enrollment.” (97% match in meaning)
• Effect of Pradaxa vs Warfarin on Bone Mass and Bone Turnover Markers
  “Study was terminated early due to low enrollment numbers.” (94% match in meaning)
• A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
  “The study was terminated due to low enrollment.” (94% match in meaning)
• Gleevec/Taxol for Patients With Uterine Papillary Serous Carcinoma
  “the study was terminated early due to poor enrollment” (94% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.